Paul Friedman

Cloudflare DNS Mimecast Microsoft Office 365 Drupal Salesforce Amazon SES

liver disease nash metabolic disease mash healthcare biotechnology life sciences biotechnology: pharmaceutical preparations health care pharmaceutical manufacturing non-alcoholic steatohepatitis metabolic dysfunction associated steatohepatitis biopharmaceutical fda approval liver disease treatment liver fibrosis clinical trials therapeutics thyroid hormone receptor oral medication accelerated approval phase 3 trial advanced liver fibrosis liver inflammation liver health drug development novel therapeutics liver-directed therapy hepatology chronic liver disease biopharmaceutical industry patient care liver fat reduction liver steatosis fibrosis stages f2 to f3 hepatic health clinical research medical affairs therapeutic potential investor relations corporate governance healthcare conference research programs drug discovery patient support medical science reimbursement strategy commercial operations life cycle management specialty care market access adverse event reporting patient advocacy market development specialty therapeutics therapeutic targets innovative solutions biopharmaceuticals metabolic dysfunction rezdiffra resmetirom thyroid hormone receptor beta agonist fda-approved medication patient-focused approach unmet medical needs healthcare providers specialist clinicians cardiovascular-metabolic diseases patient demographics market expansion therapeutic commercialization metabolic health nash treatment patient education healthcare partnerships competitive landscape industry competitors liver specialist engagement patient outcomes health wellness & fitness hospital & health care pharmaceuticals medical